[go: up one dir, main page]

EA200200097A1 - Имидазоимидазолы и триазолы в качестве противовоспалительных агентов - Google Patents

Имидазоимидазолы и триазолы в качестве противовоспалительных агентов

Info

Publication number
EA200200097A1
EA200200097A1 EA200200097A EA200200097A EA200200097A1 EA 200200097 A1 EA200200097 A1 EA 200200097A1 EA 200200097 A EA200200097 A EA 200200097A EA 200200097 A EA200200097 A EA 200200097A EA 200200097 A1 EA200200097 A1 EA 200200097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazomidasoles
triazoles
inflammatory agents
international
application
Prior art date
Application number
EA200200097A
Other languages
English (en)
Other versions
EA004932B1 (ru
Inventor
Яньпин Ву
Теренс Алфред Келли
Рене М. Лемиё
Даниел Р. Голдберг
Джонатан Эмилиан Эми
Роналд Дж. Сорсек
Original Assignee
Бёрингер Ингельхайм Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фармасьютиклз, Инк. filed Critical Бёрингер Ингельхайм Фармасьютиклз, Инк.
Publication of EA200200097A1 publication Critical patent/EA200200097A1/ru
Publication of EA004932B1 publication Critical patent/EA004932B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

В заявке описаны соединения формулы (I), которые могут использоваться для лечения или предупреждения воспалительных и опосредуемых иммунными клетками заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200097A 1999-07-21 2000-07-12 Имидазоимидазолы и имидазотриазолы в качестве противовоспалительных агентов EA004932B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14490599P 1999-07-21 1999-07-21
US15093999P 1999-08-26 1999-08-26
PCT/US2000/018884 WO2001007440A1 (en) 1999-07-21 2000-07-12 Imidazoimidazoles and triazoles as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
EA200200097A1 true EA200200097A1 (ru) 2002-08-29
EA004932B1 EA004932B1 (ru) 2004-10-28

Family

ID=26842483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200097A EA004932B1 (ru) 1999-07-21 2000-07-12 Имидазоимидазолы и имидазотриазолы в качестве противовоспалительных агентов

Country Status (33)

Country Link
US (3) US6492408B1 (ru)
EP (1) EP1216247B1 (ru)
JP (1) JP2003505460A (ru)
KR (2) KR20070053363A (ru)
CN (1) CN1166667C (ru)
AR (1) AR029383A1 (ru)
AT (1) ATE413402T1 (ru)
AU (1) AU776496B2 (ru)
BG (1) BG65865B1 (ru)
BR (1) BR0012666A (ru)
CA (1) CA2383017A1 (ru)
CO (1) CO5180640A1 (ru)
CZ (1) CZ2002191A3 (ru)
DE (1) DE60040751D1 (ru)
DK (1) DK1216247T3 (ru)
EA (1) EA004932B1 (ru)
EE (1) EE04965B1 (ru)
ES (1) ES2316374T3 (ru)
HK (1) HK1048637B (ru)
HR (1) HRP20020051A2 (ru)
HU (1) HUP0203971A3 (ru)
IL (2) IL147296A0 (ru)
MX (1) MXPA02000540A (ru)
MY (1) MY155218A (ru)
NO (1) NO322707B1 (ru)
NZ (1) NZ517217A (ru)
PL (1) PL352755A1 (ru)
RS (1) RS50260B (ru)
SK (1) SK286912B6 (ru)
TR (1) TR200200160T2 (ru)
TW (1) TWI261591B (ru)
UY (1) UY26249A1 (ru)
WO (1) WO2001007440A1 (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
MXPA03000914A (es) 2000-08-09 2003-10-06 Boehringer Ingelheim Pharma Sintesis de (r)-3-(4 -bromobencil) -1-(3, 5-diclorofenil) -5-yodo-3 -metil-1-h -imidazo[1, 2-a]imidazol -2-ona.
US20030008848A1 (en) * 2000-12-19 2003-01-09 Fleck Roman Wolfgang Small molecules useful in the treatment of inflammatory disease
CZ20032044A3 (cs) * 2001-01-26 2003-12-17 Ristol-Myers Squibb Company Imidazolylové deriváty jako inhibitory faktoru uvolňujícího kortikotropin
DK1405852T3 (da) * 2001-06-20 2012-08-27 Daiichi Sankyo Co Ltd Diaminderivater
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
JP4331595B2 (ja) * 2001-08-09 2009-09-16 第一三共株式会社 ジアミン誘導体
FR2829766A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
US6974815B2 (en) 2002-10-11 2005-12-13 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
EP1712553A3 (en) * 2002-10-30 2006-11-02 Boehringer Ingelheim Pharmaceuticals, Inc. Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
BRPI0512213A (pt) * 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
JP2008503460A (ja) * 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
AU2005269634A1 (en) * 2004-07-27 2006-02-09 Boehringer Ingelheim International, Gmbh Synthesis of 6,7-dihydro-5H-imidazo(1,2-a)imidazole-3-sulfonic acid amides
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
MX2007004527A (es) * 2004-10-12 2007-09-21 Decode Genetics Inc Acidos carboxilicos biciclicos peri-sustituidos para enfermedad de arteria oclusiva.
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
CA2593515A1 (en) * 2005-01-14 2006-07-20 Wyeth Amino-imidazolones for the inhibition of beta-secretase
WO2006083760A1 (en) * 2005-02-01 2006-08-10 Wyeth AMINO-PYRIDINES AS INHIBITORS OF β-SECRETASE
BRPI0606902A2 (pt) 2005-02-14 2009-07-28 Wyeth Corp composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
US7572921B2 (en) * 2005-04-05 2009-08-11 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
US7589114B2 (en) * 2005-04-06 2009-09-15 Boehringer Ingelheim International Gmbh Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-azetidine-carboxylic acids, esters and amides
MX2007014392A (es) * 2005-05-19 2008-02-06 Boehringer Ingelheim Int Derivados del acido 6, 7-dihidro-5h-imidazo [1,2-a] imidazol-3-sulfonico.
PE20070135A1 (es) 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
CN101213183A (zh) * 2005-06-30 2008-07-02 惠氏公司 氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
PE20070461A1 (es) * 2005-09-26 2007-05-10 Wyeth Corp Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona como inhibidores de b-secretasa
EP1966185A2 (en) * 2005-12-19 2008-09-10 Wyeth a Corporation of the State of Delaware 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION
WO2007084882A2 (en) * 2006-01-20 2007-07-26 Boehringer Ingelheim International Gmbh Process for the preparation of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides and intermediates used therein
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2644600B1 (en) 2006-06-12 2017-01-11 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
MX2009003102A (es) * 2006-09-21 2009-04-01 Wyeth Corp INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA.
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
CL2008000784A1 (es) * 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
PE20090617A1 (es) * 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
BRPI0819831A2 (pt) * 2007-11-29 2019-09-24 Boehringer Ingelheim Int derivados de amidas de áciodo 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-carboxílico
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
EP2445914B1 (en) 2009-06-02 2015-07-22 Boehringer Ingelheim International GmbH DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
BRPI1012581A2 (pt) * 2009-06-02 2016-03-29 Boehringer Ingelheim Int derivados de amidas de ácido 6, 7-di-hidro-5h-imidazol[1,2-a]imidazol-3-carboxílico
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP2448581B1 (en) * 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
WO2012083246A1 (en) 2010-12-17 2012-06-21 Agios Pharmaceuticals, Inc. Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
MX336022B (es) 2010-12-21 2016-01-06 Agios Pharmaceuticals Inc Activadores de pkm2 bicíclicos.
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
PT2704721T (pt) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CA2841252C (en) * 2011-07-13 2019-02-26 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
SI3307271T1 (sl) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Postopki za uporabo aktivatorjev piruvat kinaze
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter
PL248267B1 (pl) * 2023-04-13 2025-11-17 Uniwersytet Medyczny W Lublinie 1-arylo-6-hydroksyimino-5(1H)okso-2,3-dihydroimidazo[1,2-a] imidazole oraz sposób ich wytwarzania oraz ich zastosowanie

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2015493A1 (ru) 1968-08-12 1970-04-30 Sumitomo Chemical Co
DK123717B (da) 1968-11-25 1972-07-24 Sumitomo Chemical Co 3-(3',5'-Dihalogenphenyl)-imidazolidin-2,4-dionderivater med mirobicid virkning.
FR2075356A5 (en) 1970-01-12 1971-10-08 Sumitomo Chemical Co N-aryl cyclic imides preparation
JPS5136332B1 (ru) 1970-12-09 1976-10-07
JPS5188631A (en) 1975-01-31 1976-08-03 Hiiryoyosatsukinzai oyobi sonoseizoho
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
JPS60246374A (ja) * 1984-05-18 1985-12-06 Daicel Chem Ind Ltd ２−アミノイミダゾリン化合物の製造方法
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US4977270A (en) 1988-12-01 1990-12-11 Ici Americas Inc. Substituted 2,4-dioxodiazolidines and -thiadiazolidines and their use as herbicides
US4911748A (en) 1988-12-22 1990-03-27 Ici Americas Inc. Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones
JPH04273877A (ja) * 1991-02-28 1992-09-30 Sumitomo Pharmaceut Co Ltd 新規なイミダゾール誘導体
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
SK117499A3 (en) * 1997-03-03 2000-05-16 Boehringer Ingelheim Pharma Small molecules useful in the treatment of inflammatory and immune cell-mediated diseases, small molecules and pharmaceutical composition with their content
US6630492B1 (en) 1997-08-28 2003-10-07 Novartis Ag Lymphocyte function antigen-1 antagonists
CN1191063C (zh) 1998-03-27 2005-03-02 基因技术股份有限公司 治疗cd11/cd18粘附受体所介导疾病的拮抗剂
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
EP1399155B1 (en) * 1999-07-21 2008-05-28 Boehringer Ingelheim Pharmaceuticals Inc. Small molecules useful in the treatment of inflammatory disease
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US7589114B2 (en) * 2005-04-06 2009-09-15 Boehringer Ingelheim International Gmbh Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-azetidine-carboxylic acids, esters and amides
MX2007014392A (es) * 2005-05-19 2008-02-06 Boehringer Ingelheim Int Derivados del acido 6, 7-dihidro-5h-imidazo [1,2-a] imidazol-3-sulfonico.

Also Published As

Publication number Publication date
EE200200028A (et) 2003-04-15
HUP0203971A3 (en) 2005-01-28
TR200200160T2 (tr) 2002-10-21
CZ2002191A3 (cs) 2002-04-17
AU6209100A (en) 2001-02-13
NO20020275L (no) 2002-02-04
HRP20020051A2 (en) 2003-10-31
US6492408B1 (en) 2002-12-10
IL147296A0 (en) 2002-08-14
EE04965B1 (et) 2008-02-15
ATE413402T1 (de) 2008-11-15
PL352755A1 (en) 2003-09-08
IL147296A (en) 2006-07-05
US20030203955A1 (en) 2003-10-30
KR20020015074A (ko) 2002-02-27
NO20020275D0 (no) 2002-01-18
DE60040751D1 (de) 2008-12-18
EP1216247B1 (en) 2008-11-05
HK1048637B (zh) 2005-02-25
CO5180640A1 (es) 2002-07-30
BG106312A (bg) 2002-09-30
CN1166667C (zh) 2004-09-15
WO2001007440A1 (en) 2001-02-01
BR0012666A (pt) 2002-04-09
YU3902A (sh) 2006-01-16
SK286912B6 (sk) 2009-07-06
CA2383017A1 (en) 2001-02-01
US20040116426A1 (en) 2004-06-17
AR029383A1 (es) 2003-06-25
RS50260B (sr) 2009-07-15
KR20070053363A (ko) 2007-05-23
UY26249A1 (es) 2001-01-31
JP2003505460A (ja) 2003-02-12
US6689804B2 (en) 2004-02-10
KR100767200B1 (ko) 2007-10-17
TWI261591B (en) 2006-09-11
DK1216247T3 (da) 2009-02-23
AU776496B2 (en) 2004-09-09
EA004932B1 (ru) 2004-10-28
MY155218A (en) 2015-09-30
HK1048637A1 (en) 2003-04-11
US7550494B2 (en) 2009-06-23
BG65865B1 (bg) 2010-03-31
HUP0203971A2 (hu) 2003-03-28
CN1372562A (zh) 2002-10-02
EP1216247A1 (en) 2002-06-26
ES2316374T3 (es) 2009-04-16
MXPA02000540A (es) 2002-07-02
SK2562002A3 (en) 2002-07-02
NO322707B1 (no) 2006-11-27
NZ517217A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA200100772A1 (ru) Бензогетероциклы и их применение в качестве мек ингибиторов
EA199900936A1 (ru) Фунгицидные трифторметилалкиламинотриазолопиримидины
EA199900620A1 (ru) Фталазиноны
EA200100103A1 (ru) Ингибиторы адгезии клеток
EA200101036A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
EA199800667A1 (ru) Новые фенантридины
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
EA200100757A1 (ru) Хинолинкарбоксамиды в качестве противовирусных агентов
BG101422A (bg) Бензоксазолни производни като бронхоразширяващи средства
EA200400006A1 (ru) Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
EA200400648A1 (ru) N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200100127A1 (ru) Производные фенилксантина
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
EA200200545A1 (ru) Онколитические комбинации для лечения рака

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU